3D Systems Corporation (NYSE: DDD) — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone Q4 report; the supplied filing text does not provide clear standalone fourth-quarter financial results. Filed August 13, 2024, after the filing deadline.
Business context
3D Systems sells 3D printers, materials, software and related services for healthcare and industrial markets. Its two reportable segments are Healthcare Solutions and Industrial Solutions. Services include maintenance, advanced manufacturing and application engineering.
Financial results
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue | $488.1 million | $538.0 million |
| Products revenue | $328.7 million | $395.4 million |
| Services revenue | $159.3 million | $142.6 million |
| Gross profit / margin | $196.4 million / 40.2% | $214.2 million / 39.8% |
| Operating loss | $406.0 million | $117.0 million |
| Net loss attributable to 3D Systems | $362.7 million | $122.7 million |
| Basic and diluted loss per share | $2.79 | $0.96 |
| Adjusted EBITDA (non-GAAP) | $(26.3) million | $(5.8) million |
| Cash used in operating activities | $80.7 million | $70.0 million |
Cash and cash equivalents were $331.5 million at year-end, down from $388.1 million; the company had no short-term investments at year-end, versus $180.6 million in 2022. Current assets were $627.8 million and current liabilities $147.2 million. Operating working capital, as defined in the filing, was $476.1 million, down 30.2%.
Year-end debt included $324.9 million principal of 0% convertible notes due November 2026; the balance-sheet carrying amount, net of issuance costs, was $319.4 million. In December 2023, the company repurchased $135.1 million principal for $100.6 million, recognizing a $32.2 million gain. On March 8, 2024, it repurchased a further $110.5 million principal for $87.2 million; the filing reports approximately $214.4 million of notes remaining after that transaction.
Material changes versus 2022
- Revenue declined 9.3%, primarily because product revenue fell 16.9%; service revenue increased 11.7%.
- Healthcare Solutions revenue fell 18.3% to $213.2 million, largely from lower dental-market sales, including lower printer sales to a key customer. Industrial Solutions revenue edged down 0.8% to $274.9 million.
- Product gross margin decreased to 38.2% from 40.0%; services gross margin improved to 44.5% from 39.4%. A $4.5 million cumulative catch-up adjustment on collaboration milestones contributed to reported service gross profit.
- Operating loss included $302.8 million of goodwill and intangible-asset impairments, including a $279.8 million write-off of all Industrial Solutions goodwill. Net loss was partly offset by the debt-repurchase gain and higher interest income.
- Cash used in operations increased by $10.7 million. Cash flows also reflected $100.6 million of debt repayments, $29.2 million of acquisitions and other investments, and $27.2 million of capital expenditures.
- Restructuring reduced headcount and targeted manufacturing, facilities and third-party costs. The company recorded $8.2 million of restructuring charges in 2023.
Outlook, management commentary and risks
- Management expects restructuring actions to generate annualized savings of $50 million to $65 million beginning in fiscal 2025, with the plan and associated cash settlements expected to be substantially complete by December 31, 2024. Facility-exit savings and timing remain uncertain.
- The company said cash, expected operating cash flow and potential financing sources should meet foreseeable requirements, but it also disclosed operating cash outflows and identified the ability to generate cash or raise capital as a risk.
- Management identified macroeconomic pressure, customer financing constraints, supply-chain dependence, uneven sales timing, foreign-exchange exposure and product competition as risks. One customer represented 15% of 2023 revenue, down from 23% in 2022; revenue from that customer declined approximately 41% year over year.
- Management reported material weaknesses in financial reporting controls, including revenue recognition and pricing controls, close and disclosure review, technical accounting review, and the control environment. Management and the auditor concluded internal control over financial reporting was ineffective; the auditor issued an adverse opinion on those controls. The auditor gave an unqualified opinion on the financial statements.
- The delayed 10-K and 2024 first-quarter 10-Q triggered defaults under the convertible-note indenture. The filing states the defaults could become an event of default if not cured within the applicable cure period; as of August 13, 2024, the cure period had not been initiated and no special interest or holder action had occurred. Late filings also made the company ineligible to use Form S-3 until potentially June 1, 2025, subject to requirements.
- An SEC formal investigation, ongoing since 2022, remained unresolved. Export-control settlements require $15.0 million in civil penalties and remedial compliance measures; a further $10.0 million suspended penalty may be payable to the extent not credited for approved measures.
- After year-end, the regenerative-medicine program was refocused on lung scaffolds following loss of partner funding for kidney and liver research. A dispute with former Volumetric owners over potential earnout payments remained in mediation as of the filing date. The company also sold the dental-focused portion of Oqton MOS in May 2024 for a de minimis amount and continued evaluating the remaining business.
Important facts for investors to verify
- Whether 2024 filings and control-remediation work resolved the note-indenture defaults and restored timely reporting and financing access.
- Cash generation, working-capital trends and the remaining convertible-note principal and repayment or refinancing options.
- Progress toward the $50 million–$65 million restructuring savings target, including actual cash costs and facility-exit outcomes.
- Revenue recovery, especially in dental and printer sales, customer concentration, and the sustainability of services growth and margins.
- Outcomes and potential costs from the SEC investigation, export-control compliance obligations and Volumetric earnout dispute.
- Results of strategic actions involving Oqton and the commercial and funding prospects for regenerative medicine programs.